TRILLIUM THERAPEUTICS INC. Share-based Payment Arrangement, Expense
TRILLIUM THERAPEUTICS INC. reported Share-based Payment Arrangement, Expense of $6.39 million for the 3-month period ending 2021-09-30, per its 10-Q filed 2021-11-12.
Discontinued › Expense Statement › Operating Expenses
us-gaap:AllocatedShareBasedCompensationExpense · last filed 2021-11-12
- TRILLIUM THERAPEUTICS INC. share-based payment arrangement, expense for the quarter ending 2021-09-30 was $6.39M, a 9.03% decline year-over-year.
- TRILLIUM THERAPEUTICS INC. share-based payment arrangement, expense for the quarter ending 2021-06-30 was $2.92M, a 22.37% decline year-over-year.
- TRILLIUM THERAPEUTICS INC. share-based payment arrangement, expense for the quarter ending 2021-03-31 was $3.02M, a 69.41% increase year-over-year.
- TRILLIUM THERAPEUTICS INC. share-based payment arrangement, expense for the quarter ending 2020-12-31 was $1.49M.
- TRILLIUM THERAPEUTICS INC. share-based payment arrangement, expense for fiscal 2020 was $14.06M, a 458.98% increase from fiscal 2019.
- TRILLIUM THERAPEUTICS INC. share-based payment arrangement, expense for fiscal 2019 was $2.52M.
| Period end | Share-based Payment Arrangement, Expense 3 month | Share-based Payment Arrangement, Expense 6 month | Share-based Payment Arrangement, Expense 9 month | Share-based Payment Arrangement, Expense 12 month |
|---|---|---|---|---|
| 2021-09-30 | $6.39M 10-Q · filed 2021-11-12 | $9.31M derived: sum of 2 quarters · filed 2021-11-12 | $12.34M 10-Q · filed 2021-11-12 | $13.83M derived: sum of 4 quarters · filed 2021-11-12 |
| 2021-06-30 | $2.92M 10-Q · filed 2021-08-13 | $5.95M 10-Q · filed 2021-08-13 | $7.44M derived: sum of 3 quarters · filed 2021-08-13 | $14.46M derived: sum of 4 quarters · filed 2021-11-12 |
| 2021-03-31 | $3.02M 10-Q · filed 2021-05-07 | $4.51M derived: sum of 2 quarters · filed 2021-05-07 | $11.54M derived: sum of 3 quarters · filed 2021-11-12 | $15.30M derived: sum of 4 quarters · filed 2021-11-12 |
| 2020-12-31 | $1.49M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-18 | $8.51M derived: sum of 2 quarters · filed 2021-11-12 | $12.28M derived: sum of 3 quarters · filed 2021-11-12 | $14.06M 10-K · filed 2021-03-18 |
| 2020-09-30 | $7.02M 10-Q · filed 2021-11-12 | $10.79M derived: sum of 2 quarters · filed 2021-11-12 | $12.58M 10-Q · filed 2021-11-12 | |
| 2020-06-30 | $3.77M 10-Q · filed 2021-08-13 | $5.55M 10-Q · filed 2021-08-13 | ||
| 2020-03-31 | $1.78M 10-Q · filed 2021-05-07 | |||
| 2019-12-31 | $2.52M 10-K · filed 2021-03-18 |